S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

Detalles Bibliográficos
Autores principales: Santini, Valeria, Platzbecker, Uwe, Fenaux, Pierre, Sekeres, Mikkael, Savona, Michael Robert, Madanat, Yazan, Campelo, María Díez, Valcárcel, David, Illmer, Thomas, Jonášová, Anna, Belohlavkova, Petra, Sherman, Laurie, Berry, Tymara, Dougherty, Souria, Shah, Sheetal, Xia, Qi, Peng, Lixian, Sun, Libo, Wan, Ying, Huang, Fei, Ikin, Annat, Navada, Shyamala, Feller, Faye, Zeidan, Amer M., Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428251/
http://dx.doi.org/10.1097/01.HS9.0000967568.52578.93
_version_ 1785090422778888192
author Santini, Valeria
Platzbecker, Uwe
Fenaux, Pierre
Sekeres, Mikkael
Savona, Michael Robert
Madanat, Yazan
Campelo, María Díez
Valcárcel, David
Illmer, Thomas
Jonášová, Anna
Belohlavkova, Petra
Sherman, Laurie
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Xia, Qi
Peng, Lixian
Sun, Libo
Wan, Ying
Huang, Fei
Ikin, Annat
Navada, Shyamala
Feller, Faye
Zeidan, Amer M.
Komrokji, Rami S.
author_facet Santini, Valeria
Platzbecker, Uwe
Fenaux, Pierre
Sekeres, Mikkael
Savona, Michael Robert
Madanat, Yazan
Campelo, María Díez
Valcárcel, David
Illmer, Thomas
Jonášová, Anna
Belohlavkova, Petra
Sherman, Laurie
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Xia, Qi
Peng, Lixian
Sun, Libo
Wan, Ying
Huang, Fei
Ikin, Annat
Navada, Shyamala
Feller, Faye
Zeidan, Amer M.
Komrokji, Rami S.
author_sort Santini, Valeria
collection PubMed
description
format Online
Article
Text
id pubmed-10428251
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104282512023-08-17 S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3 Santini, Valeria Platzbecker, Uwe Fenaux, Pierre Sekeres, Mikkael Savona, Michael Robert Madanat, Yazan Campelo, María Díez Valcárcel, David Illmer, Thomas Jonášová, Anna Belohlavkova, Petra Sherman, Laurie Berry, Tymara Dougherty, Souria Shah, Sheetal Xia, Qi Peng, Lixian Sun, Libo Wan, Ying Huang, Fei Ikin, Annat Navada, Shyamala Feller, Faye Zeidan, Amer M. Komrokji, Rami S. Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428251/ http://dx.doi.org/10.1097/01.HS9.0000967568.52578.93 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Santini, Valeria
Platzbecker, Uwe
Fenaux, Pierre
Sekeres, Mikkael
Savona, Michael Robert
Madanat, Yazan
Campelo, María Díez
Valcárcel, David
Illmer, Thomas
Jonášová, Anna
Belohlavkova, Petra
Sherman, Laurie
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Xia, Qi
Peng, Lixian
Sun, Libo
Wan, Ying
Huang, Fei
Ikin, Annat
Navada, Shyamala
Feller, Faye
Zeidan, Amer M.
Komrokji, Rami S.
S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title_full S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title_fullStr S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title_full_unstemmed S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title_short S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
title_sort s164: disease modifying activity of imetelstat in patients with heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in imerge phase 3
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428251/
http://dx.doi.org/10.1097/01.HS9.0000967568.52578.93
work_keys_str_mv AT santinivaleria s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT platzbeckeruwe s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT fenauxpierre s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT sekeresmikkael s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT savonamichaelrobert s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT madanatyazan s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT campelomariadiez s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT valcarceldavid s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT illmerthomas s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT jonasovaanna s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT belohlavkovapetra s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT shermanlaurie s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT berrytymara s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT doughertysouria s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT shahsheetal s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT xiaqi s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT penglixian s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT sunlibo s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT wanying s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT huangfei s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT ikinannat s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT navadashyamala s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT fellerfaye s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT zeidanamerm s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3
AT komrokjiramis s164diseasemodifyingactivityofimetelstatinpatientswithheavilytransfusednondel5qlowerriskmyelodysplasticsyndromesrelapsedrefractorytoerythropoiesisstimulatingagentsinimergephase3

Ejemplares similares